David A. Siegel Castle Biosciences Inc Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Castle Biosciences Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 9,900 shares of CSTL stock, worth $331,155. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,900
Previous 12,000
17.5%
Holding current value
$331,155
Previous $245,000
8.16%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding CSTL
# of Institutions
185Shares Held
27MCall Options Held
42.2KPut Options Held
9.3K-
Black Rock Inc. New York, NY3.04MShares$102 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$72.7 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.79MShares$60 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.52MShares$50.7 Million2.16% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.47MShares$49.3 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $880M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...